Oil Prices Slip as U.S.-Iran Peace Talks and Strait of Hormuz Risks Keep Markets on Edge 
U.S. Stocks End Q2 Higher as Strong Jobs Data and AI Rally Lift Wall Street 
RBA Minutes Signal Australia Central Bank Remains Ready to Raise Interest Rates if Inflation Persists 
Asian Currencies Slip as Dollar Holds Firm, Yen Near Four-Decade Low Ahead of Fed, Jobs Data 
India Manufacturing PMI Slows in June as Demand Weakens Despite Lower Cost Pressures 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Asian Stocks Mixed as South Korea Slides on Profit-Taking, Japan and China Gain on Strong Factory Data 
Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
US Egg Producers Settle Price Manipulation Probe, Agree to Pay $3.3 Million and Donate 53 Million Eggs 
Gold Price Hits Annual Low as Fed Rate Hike Bets and Sticky Inflation Weigh on Bullion 
South Korea Alleges Google Abused Android App Store Dominance, Eyes Major Fine 
Anthropic Brings Claude AI Models to Microsoft Azure Foundry With NVIDIA Blackwell GPUs 
Baidu Shares Rally as Kunlunxin Eyes $50 Billion Hong Kong IPO 
China Expands Export Controls, Adds 20 Japanese Companies to Restricted List 
Chip Stocks Rally as Samsung and SK Hynix’s $1.3 Trillion Investment Plan Boosts AI Optimism 
Kakaku.com Shares Rise as Bain Capital and LY Corp Prepare Higher Takeover Bid Than EQT 
Asian Currencies Stay Range-Bound as Investors Eye China Data, RBNZ Outlook and U.S.-Iran Ceasefire 
SK Bioscience recently inked a contract manufacturing organization (CMO) agreement with MSD which is also known as Merck & Co. The deal is for the production of the next-generation Zaire Ebola virus vaccine candidate.
The Vice Minister of the Ministry of Health and Welfare, Park Min Soo, MSD’s executive vice president Sanat Chattopadhyay, SK Bioscience’s chief executive officer Ahn Jae Yong, SK Disocvery’s vice chairman Chang Won Chey, Hillman Labs CEO, Raman Rao, and Representative of Global R&BD Kim Hoon were all present at the signing ceremony.
After the contract signing of the CMO deal with MSD, The Korea Herald reported that the stock price of SK Bioscience surged by 16.39% to KRW83,100 or about $64.04 late last week. The increase is said to be largely due to the hopes that the deal will improve the company’s slow sales performance.
In any case, SK Bioscience further confirmed the deal with MSD on Monday, May 8. It also provided more details about the CMO agreement today.
“For the growth and development of the biopharmaceutical industry, it is very important to promote cooperation between companies and establish its innovative ecosystem,” Park Min Soo said in a press release. “The Korean government is seeking various support measures, such as regulatory innovation and governance establishment, to promote cooperation between companies. We hope that this contract will continue a friendly cooperative relationship between MSD, Korea, and SK bioscience.”
MSD’s EVP and president of the manufacturing unit, Sanat Chattopadhyay, also said, “At MSD, we continue to seek innovative solutions to help expand access and help make our vaccines available when needed to people around the world. This agreement with SK bioscience, as part of our strong global manufacturing network, may enable us to further assist the global community in its response to future outbreaks of the Zaire Ebola virus.”
